Brief: Liminal Biosciences Announces First Subject Dosed In Phase 1 Clinical Trial Of Fezagepras
15/12/2020 14:40
Dec 15 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES ANNOUNCES FIRST SUBJECT DOSED IN PHASE
1
MULTIPLE ASCENDING DOSE CLINICAL TRIAL OF FEZAGEPRAS
Source text for Eikon: ID:nPn1QKmG4a
Further company coverage: LMNL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liminal BioSciences
See all newsBrief: Liminal Biosciences Announces Completion Of The Plan Of Arrangement With Structured Alpha Lp
Brief: Liminal Biosciences Files Amended Schedule 13E-3 And Supplement To Management Information Circular
Brief: Liminal Biosciences Obtains Interim Order For Proposed Arrangement With Structured Alpha Lp
U.S. STOCKS ON THE MOVE-Liminal Biosciences, Tesla, Quad/Graphics
U.S. STOCKS ON THE MOVE-T2 Biosystems, GoodRx Holdings, ShiftPixy